Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Katarína Hradská"'
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 143-150 (2023)
Telemonitoring is a great tool for vital signs monitoring in patients at high risk of severe life-threatening infections, such as haemato-oncological patients. As it can detect early symptoms of an infection, it allows early reaction and, therefore,
Externí odkaz:
https://doaj.org/article/71c907b8b1b247b3b13b077e30ee9675
Autor:
Marian Lebiedzik, Kamila Turečkova, Ingrid Majerova, Jan Nevima, Katarína Hradská, Tereza Popková, Michaela Skořupová, Roman Hájek
Publikováno v:
PLoS ONE, Vol 18, Iss 11, p e0291143 (2023)
The article examines the effectiveness of remote monitoring and the evaluation of facts about patients with hematologic malignancies using telemedicine based on SMART technologies. The project was carried out in the Department of Haematooncology of t
Externí odkaz:
https://doaj.org/article/edf54d941c7a423cafe353ea521509dc
Autor:
Jana Mihályová, Katarína Hradská, Tomáš Jelínek, Benjamin Motais, Piotr Celichowski, Roman Hájek
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 21, p 11470 (2021)
Over the last few years, treatment principles have been changed towards more targeted therapy for many B-cell lymphoma subtypes and in chronic lymphocytic leukemia (CLL). Immunotherapeutic modalities, namely monoclonal antibodies (mAbs), bispecific a
Externí odkaz:
https://doaj.org/article/007347c5ac0b458cb176804d58895469
Autor:
Katarína Hradská, Tereza Popková, Michaela Skořupová, Jana Mihályová, Tomáš Jelínek, Jana Lančová, Norbert Schellong, Roman Hájek
Publikováno v:
Cancer management and research. 14
KatarÃna Hradská,1,2 Tereza Popková,1,2 Michaela Skořupová,1,2 Jana Mihályová,2 Tomáš JelÃnek,2 Jana Lančová,3 Norbert Schellong,3 Roman Hájek1,2 1Faculty of Science, University of Ostrava, Ostrava, Czec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a48e360078b000cde6a4cd83867be33
https://pubmed.ncbi.nlm.nih.gov/35547597
https://pubmed.ncbi.nlm.nih.gov/35547597
Autor:
Ondrej Šušol, Barbora Hájková, Tomáš Jelínek, Jana Mihályová, Katarína Hradská, Michal Kaščák, Kateřina Benková, Hana Zelena, Jan Martínek, Roman Hájek
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa515614d6d6feb1e22d6fbb7fed5f59
https://doi.org/10.2139/ssrn.3960655
https://doi.org/10.2139/ssrn.3960655
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Immune checkpoint inhibitors (ICIs), especially those targeting the programmed-death 1 (PD-1) receptor and its ligands, have become indispensable agents in solid tumor anti-cancer therapy. Concerning hematological malignancies, only nivolumab and pem
Externí odkaz:
https://doaj.org/article/8c1cb7b1961b4f9e9c7ab7a71dbfb627